Libroxar (Buprenorphine, Naloxone)

Buprenorphine binds tightly to μ‑opioid receptors but activates them only partially, providing enough opioid effect to relieve withdrawal while limiting the ceiling for respiratory depression. This partial agonism eases cravings and stabilizes patients without producing the full opioid high.

The dose of Libroxar is individualized. A qualified prescriber determines the appropriate strength and dosing schedule based on the patient’s clinical condition, prior opioid exposure, and response to therapy. Patients should follow the prescribing information provided by their healthcare professional.

Safety in pregnancy and lactation has not been fully established. The medication should be used only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians must evaluate each case carefully and discuss alternatives when possible.

To order Libroxar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Libroxar and methadone are used for opioid dependence, but Libroxar combines a partial agonist (buprenorphine) with an antagonist (naloxone) to reduce misuse potential, while methadone is a full agonist. Libroxar generally has a lower risk of respiratory depression and a ceiling effect, whereas methadone may require more intensive monitoring.

Libroxar should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date indicated on the label.

Libroxar is taken orally, usually as a tablet, under the supervision of a healthcare professional. The tablet should be swallowed whole with water and not chewed or crushed. Dosing frequency and timing are determined by the prescriber based on the individual treatment plan.

The most serious risks include respiratory depression, severe hypotension, and allergic reactions such as anaphylaxis. Patients should be monitored closely for signs of breathing difficulty, sudden drops in blood pressure, or skin manifestations, and medical attention should be sought immediately if these occur.

Libroxar is contraindicated in individuals with known hypersensitivity to buprenorphine, naloxone, or any excipients in the formulation. It should also be avoided in patients with severe respiratory compromise, acute severe asthma, or those currently using opioid antagonists for opioid overdose reversal.